A cost-consequence analysis of long-acting injectable risperidone in schizophrenia: A one-year mirror-image study with national claim-based database in Taiwan

作者：Chang Hui Chih; Tang Chao Hsiun; Huang Sheng Tzu; McCrone Paul; Su Kuan Pin^*

来源：Journal of Psychiatric Research, 2012, 46(6): 751-756.

DOI：10.1016/j.jpsychires.2012.02.019

• Antipsychotics
• Mirror-image study
• Service costs
• Relapse Psychiatric Inpatients Medical Claims Data (PIMC)

Objective: The development of long-acting atypical antipsychotics has provided a new paradigm for schizophrenia treatment. The economic effectiveness of risperidone long-acting injection (RLAI) on service costs has, however, never been studied in the real world with national claim-based database. %26lt;br%26gt;Method: To assess the change of service utilization and costs for schizophrenia before and after RLAI treatment, we conducted this 1-year mirror-image study with Taiwanese national claimed-data. Comparison was made for service sectors (the number of visits, acute admissions and relapse events) and cost components (outpatient, inpatient, emergency, medication and non-medication costs). %26lt;br%26gt;Results: Service uses reduced in the post-RLAI period, along with a reduction of 34% and 32% on total inpatient services costs and inpatient non-medication costs, respectively (p %26lt; 0.005). However, overall psychiatric service costs went up by 26%, with an increase of 190% on total outpatient service costs and 177% on overall medication costs (p %26lt; 0.0001). %26lt;br%26gt;Conclusions: This 1-year mirror-image analysis showed that RLAI treatment was associated with reductions of service uses; however, overall psychiatric service costs were compromised by costs incurred from increased utilization of outpatient service and RLAI medication costs under the context of healthcare in Taiwan.

• 出版日期2012-6
• 单位中国医科大学